Insights on Personalized Treatment Through Theranostics

Theranostics combines the concepts of therapy and diagnostics, using molecular imaging to identify specific biological targets and a corresponding therapeutic agent to treat those targets. In many applications, a diagnostic radiotracer is first used to visualize whether a target is present. If the target is sufficiently expressed, a related therapeutic radiopharmaceutical may be considered. This approach can help clinicians make treatment decisions based on characteristics of an individual patients disease rather than relying only on anatomical information.

How Theranostics Supports Personalized Treatment

The personalized aspect of theranostics comes from using molecular information to guide treatment selection. Imaging techniques such as PET can show how a particular biological target is distributed within the body. This information can help healthcare professionals determine whether a patient may be appropriate for a targeted radiopharmaceutical treatment.

Important elements of this approach include:

• Target identification: Molecular imaging can identify disease sites that contain a specific biological target.
• Patient selection: Imaging findings can help determine whether a targeted therapy is appropriate for an individual patient.
• Treatment planning: Disease distribution, organ function, previous treatments, and other clinical factors can contribute to treatment decisions.
• Response monitoring: Follow up imaging can provide information about how disease responds during or after treatment.

Theranostics is already used in several areas of oncology. Examples include radiopharmaceutical approaches involving prostate-specific membrane antigen in advanced prostate cancer and somatostatin receptors in neuroendocrine tumors. The National Cancer Institute notes that several radiopharmaceutical therapies have received FDA approval for specific cancer indications.

Future Developments in Theranostic Personalized Care

Research is continuing to explore how theranostics can become more individualized and precise. One important area is dosimetry, which involves estimating radiation absorbed by tumors and healthy organs. Post-treatment imaging and dosimetry may provide additional information for treatment management and could support adjustments based on an individual patients response and radiation exposure.

Emerging developments include:

• Artificial intelligence: AI may help analyze medical images and identify patterns that support treatment planning and response assessment.
• Biomarkers: Blood-based and molecular biomarkers are being investigated to improve patient selection and identify treatment resistance.
• Advanced imaging: Improved PET and SPECT technologies may provide more detailed information about disease biology.
• Personalized dosimetry: Research is examining how absorbed radiation doses can be incorporated into individualized treatment strategies.
• Multidisciplinary care: Nuclear medicine specialists, oncologists, radiologists, physicists, and other professionals may work together to evaluate treatment options.

As evidence continues to develop, theranostics may become an increasingly important component of precision medicine. However, its suitability depends on the disease, available molecular targets, imaging findings, overall health, organ function, and established clinical evidence. Treatment decisions should therefore be made by qualified healthcare professionals based on individual clinical circumstances.

Theranostics represents a developing model in which diagnosis and treatment are closely connected. By identifying molecular targets before therapy and monitoring disease afterward, the approach provides a framework for more individualized care. Continued research into imaging, biomarkers, dosimetry, and AI may further clarify how theranostics can be incorporated into personalized treatment while maintaining appropriate standards for safety and effectiveness.